Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Disalcid

(Salsalate)

ApprovedSmall molecule

JJoslin Diabetes Center

Salsalate is used to reduce pain, fever, and inflammation caused by conditions like arthritis and other joint diseases. It works similarly to aspirin but is gentler on the stomach.[2] Disalcid is currently approved and in use across 26 indications[4].[1]

Disalcid is one of 679 small molecule programs targeting Insulin resistance. It is currently in Approved.

26

Indications

30

Total Trials

2

Active Trials

678

Competitors

Pipeline

Status by Indication[4][1]

Indication

Insulin ResistanceActive, not recruiting

Cardiovascular DiseaseActive, not recruiting

Endothelial DysfunctionActive, not recruiting

Peripheral NeuropathyActive, not recruiting

Alcoholic Fatty Liver DiseaseActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Alzheimer DiseaseActive, not recruiting

AtherosclerosisActive, not recruiting

Progressive Supranuclear PalsyActive, not recruiting

Anemia (phenotype)Active, not recruiting

Insulin ResistancePhase 1

Active, not recruiting

Cardiovascular DiseasePhase 2/Phase 3

Active, not recruiting

Endothelial DysfunctionPhase 2

Active, not recruiting

Peripheral NeuropathyPhase 2

Active, not recruiting

Alcoholic Fatty Liver DiseaseApproved

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Alzheimer DiseasePhase 1

Active, not recruiting

AtherosclerosisPhase 2

Active, not recruiting

Progressive Supranuclear PalsyPhase 1

Active, not recruiting

Anemia (phenotype)Phase 2

Active, not recruiting

Showing 10 of 24 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Disalcid

JJoslin Diabetes Center

Jardiance

Boehringer Ingelheim

NOVOLIN R

Cysteine Hydrochloride

Cecon

MMcGuff Pharmaceuticals, Inc.

Forxiga

Lovaza

Sulfonylureas

Acipimox

Boehringer Ingelheim

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

E-Cigarette Use

NCT06489249

Q3 2027

Phase 1/2Recruiting

Peripheral Neuropathy

NCT05169060

Clinical

Trials by Indication[1]

Insulin resistance4 trials

The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00339833·54 enrolled

Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

Completed·VVA Office of Research and Development·Phase 2/3·NCT00330733·71 enrolled

Salsalate for Insulin Resistance in Schizophrenia

Completed·UUniversity of Maryland, Baltimore·N/A·NCT01182727·13 enrolled

Show 1 more trial

Effect of Salicylate on Glucose Metabolism in Insulin Resistance States

Completed·JJoslin Diabetes Center·Phase 1/2·NCT00258128·17 enrolled

Type 2 Diabetes2 trials

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Completed·JJoslin Diabetes Center·Phase 2/3·NCT00799643·638 enrolled

Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)

Completed·JJoslin Diabetes Center·Phase 2/3·NCT00392678·277 enrolled

Inflammation2 trials

Inflammation Inhibition in Prediabetic Humans

Terminated·GGary L. Pierce·Phase 2·NCT01977417·21 enrolled

The Study of Inflammation on Blood Glucose Levels in Obese People

Completed·JJoslin Diabetes Center·Phase 2·NCT00258115·20 enrolled

Polycystic Ovary Syndrome2 trials

Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction

Completed·UUniversity of Illinois at Chicago·Phase 2·NCT03229408·60 enrolled

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

Terminated·IIndiana University·Phase 1·NCT01489319·47 enrolled

Peripheral Neuropathy2 trials

Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy

Completed·UUniversity of Michigan·Phase 2·NCT01480297·8 enrolled

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

Recruiting·UUniversity of Iowa·Phase 1/2·NCT05169060·100 enrolled

18 more indications

Hypertension1 trial

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

Completed·EEmory University·N/A·NCT02406586·36 enrolled

Vascular Dysfunction1 trial

Effect of Salsalate on Bed Rest-Induced Vascular Dysfunction

Completed·—·Phase 1·NCT00553995·60 enrolled

Atherosclerosis1 trial

Inflammation and Vascular Function in Atherosclerosis

Completed·—·Phase 2/3·NCT00760019·58 enrolled

Cardiovascular Disease1 trial

Targeting Inflammation Using Salsalate in CardioVascular Disease

Completed·JJoslin Diabetes Center·Phase 2/3·NCT00624923·340 enrolled

Anemia1 trial

Trial To Evaluate the Efficacy of Oral Salsalate in the Treatment of Older Adults With Unexplained Anemia

Terminated·HHarvey Jay Cohen·Phase 2·NCT01506726·11 enrolled

CLE1 trial

Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?

Completed·SStanford University·N/A·NCT02007577·41 enrolled

Acute Myeloid Leukemia1 trial

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT04146038·5 enrolled

Progressive Supranuclear Palsy1 trial

A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy

Completed·AAdam Boxer·Phase 1·NCT02422485·10 enrolled

Alcoholic Fatty Liver Disease1 trial

The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease

Completed·KKorea University Guro Hospital·Phase 4·NCT03222206·34 enrolled

Mild to Moderate Alzheimer's Disease1 trial

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Completed·AAdam Boxer·Phase 1·NCT03277573·40 enrolled

Type 1 Diabetes1 trial

Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy

Completed·UUniversity of Michigan·Phase 2/3·NCT02936843·61 enrolled

Schizophrenia1 trial

Salsalate as an Adjunctive Treatment for Patients With Schizophrenia

Completed·UUniversity of Massachusetts, Worcester·Phase 4·NCT01578486·17 enrolled

Endothelial Dysfunction1 trial

Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT01046682·40 enrolled

Cardiovascular1 trial

Targeting Inflammation to Treat Cardiovascular Aging

Completed·GGary L. Pierce·Phase 2·NCT01775865·59 enrolled

Cardiac Surgery1 trial

Oral Peri-operative TIming of Metformin (or) Salsalate to Improve Non-cardiac Surgery Glucose Control

Withdrawn·MMcMaster University·Phase 1·NCT03816488

Infiltration1 trial

Using Salsalate to Target Adipocyte Macrophage Infiltration

Completed·UUniversity of Southern California·Phase 1·NCT02130804·30 enrolled

E-cigarette Use1 trial

Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use

Recruiting·UUniversity of Iowa·Phase 1·NCT06489249·24 enrolled

Preeclampsia1 trial

Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia

Completed·UUniversity of Iowa·Phase 1·NCT03482440·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 30 trial records for Salsalate. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Disalcid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Salsalate compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Salsalate. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — Joslin Diabetes Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: JJoslin Diabetes Center

Related News